A one-stop-shop CRO bringing together innovative platforms, strategic solutions and specialized expertise to drive drug development and advance diverse fields of research.
Policies, Terms & Conditions
Huningue, FR – 08/12/2023
Firalis Molecular Precision (“FMP” or “the company”), a fast-growing Contract Research Organization (CRO) providing multi-omics solutions for biomarker discovery, clinical testing and IVD kit production, announces a strategic leap in its genomics capabilities through the acquisition of the Illumina NovaSeq X Plus Sequencing System (“the technology” or “it”).
The production-scale sequencer complements FMP’s existing range of next-generation sequencing technologies, contributing to a comprehensive suite of solutions that cater to the diverse needs of FMP’s clients.
It will empower FMP to significantly increase its capacity to process large volumes of genomic data swiftly and efficiently, providing clients with faster and more comprehensive sequencing services. Indeed, the primary focus of this initiative is to assist clients in their research endeavors. FMP aims to provide researchers, healthcare professionals and academic organizations with the advanced tools they need to accelerate discoveries across diverse therapeutic areas.
The Illumina NovaSeq X Plus Sequencing System is powered by XLEAP-SBS chemistry, a sequencing by synthesis (SBS)-based chemistry, representing a leap forward in sequencing technology. This chemistry ensures not only high throughput but also accuracy and reliability in genomic data analysis.
The technology leverages the DRAGEN Bio-IT Platform, a cutting-edge software enabling fast and efficient next-generation sequencing data analysis.
“The acquisition of the Illumina® NovaSeq X Plus is a major step in the development of our NGS service offerings,” says Dr. Eric Schordan, FMP’s CSO. “We will be able to provide to our customers the highest NGS sample analysis quality combined to a competitive cost in France by our outstanding team”.
Disclaimer
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated benefits, capabilities, and performance of the Illumina NovaSeq X Plus Sequencing System, as well as FMP’s expectations, beliefs, plans, intentions, and strategies regarding the acquisition and utilization of this technology. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of FMP to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the potential impact of external factors such as regulatory changes, market conditions, and technological developments, as well as the inherent risks associated with the adoption of new technologies. FMP undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This disclaimer is in addition to, and not in lieu of, any other disclaimers or limitations of liability contained in any other communications of FMP or its representatives.
About Firalis Molecular Precision
Firalis Molecular Precision (FMP) is an emerging omics-powered CRO (Contract Research Organization) based in Huningue, France and in Cambridge, USA. FMP uses the latest cutting-edge technologies and a range of services (biobanking, multiomics-powered bioanalysis, bioinformatics, assay development and kit manufacturing) to provide support in biomarker discovery, clinical testing and IVD kit production endeavours.
Visit us at: http://www.firalismolecularprecision.com. or contact our experts. Connect with us on LinkedIn and Twitter.
Firalis Molecular Precision Media Relations
E-mail: marketing@firalis.com
Share this article on your socials